Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: A cohort study

Diabetes, Obesity and Metabolism

Volumn 16, Issue 12, 2014, Pages 1247-1256

  Gokhale, M ^a   Buse, J B ^b   Gray, C L ^a   Pate, V ^a   Marquis, M A ^a   Sturmer T ^a  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antidiabetic drug; DPP IV inhibitor; Incretin therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD ANALYSIS; CANCER INCIDENCE; CANCER RISK; CATARACT; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; DEPRESSION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIAGNOSTIC PROCEDURE; DRUG USE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEALTH CARE UTILIZATION; HUMAN; INFLUENZA VACCINATION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICARE; PANCREAS CANCER; PANCREATITIS; PROBABILITY; PROPENSITY SCORE; TOBACCO USE; TREATMENT DURATION; CHEMICALLY INDUCED; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; INCIDENCE; MIDDLE AGED; MORTALITY; ODDS RATIO; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODEL; TIME; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MEDICARE; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84920391308     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12379     Document Type: Article

References (41)

1. Gallwitz B. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes Metab Syndr Obes 2013; 6: 1-9.
2. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
3. Information for Healthcare Professionals - acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm. Accessed 20 April 2013.
4. Highlights of prescribing information: Januvia. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021995s019lbl.pdf. Accessed 20 April 2013.
5. Highlights of prescribing information: Janumet XR. Available form URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202270s003lbl.pdf. Accessed 20 April 2013.
6. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-156.
7. FDA 2011 Adverse Event Reporting System. Available from URL: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm. Accessed 10 April 2013.
8. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies - review of the scientific evidence. J Clin Endocrinol Metab 2011; 96: 2027-2031.
9. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62: 2595-2604.
10. Kahn SE. Incretin therapy and islet pathology - a time for caution. Diabetes 2013; 62: 2178-2180.
11. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Available from URL: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm344232.htm. Accessed 20 April 2013.
12. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
13. White WB, Cannon CP, Heller SR. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
14. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-2354.
15. Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-1027.
16. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013; 173: 534-539.
17. Strengths and limitations of CMS administrative data in research. Available from URL: http://www.resdac.org/resconnect/articles/156. Accessed 20 April 2013.
18. Setoguchi S, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S. Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control 2007; 18: 561-569.
19. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
20. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology 2003; 14: 680-686.
21. Kurth T, Walker AM, Glynn RJ et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006; 163: 262-270.
22. Sturmer T, Rothman KJ, Glynn RJ. Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiol Drug Saf 2006; 15: 698-709.
23. Bowker SL, Richardson K, Marra CA, Johnson JA. Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women. Diabetes Care 2011; 34: 2542-2544.
24. Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011; 54: 2263-2271.
25. Ferrara A, Lewis JD, Quesenberry CP et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011; 34: 923-929.
26. Huxley R, Ansary-Moghaddam A, Berrington de GA, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-2083.
27. Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 510-519.
28. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
29. Sturmer T, Jonsson FM, Poole C, Brookhart MA. Nonexperimental comparative effectiveness research using linked healthcare databases. Epidemiology 2011; 22: 298-301.
30. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 2007; 82: 143-156.
31. SEER Stat Fact Sheets: Pancreas. Available from URL: http://seer.cancer.gov/statfacts/html/pancreas.html#incidence-mortality. Accessed 15 April 2013.
32. Surveillance Epidemiology and End results (SEER) Statistics Stratified by Age. Available from URL: http://seer.cancer.gov/faststats/selections.php?series=age. Accessed 10 April 2013.
33. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer: A meta-analysis. JAMA 1995; 273: 1605-1609.
34. Larsson SC, Permert J, Hakansson N, Näslund I, Bergkvist L, Wolk A. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br J Cancer 2005; 93: 1310-1315.
35. Fuchs CS, Colditz GA, Stampfer MJ et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 1996; 156: 2255-2260.
36. Lynch SM, Vrieling A, Lubin JH et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009; 170: 403-413.
37. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.
38. Bailey CJ. Interpreting adverse signals in Diabetes Drug Development Programs. Diabetes Care 2013; 36: 2098-2106.
39. Brass EP. Assessing the benefit-risk for new drugs: are the FDA's endocrinologic and metabolic drugs advisory committee and the division of metabolism and endocrinology products in sync? Diabetes Care 2013; 36: 1823-1826.
40. Cefalu WT, Rosenstock J, Henry RR, Riddle M. Signals and noise in drug safety analyses: the incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance. Diabetes Care 2013; 36: 1804-1806.
41. Egan AG, Blind E, Dunder K et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014; 370: 794-797.